A 52-week, open-label study evaluating the safety and efficacy of tabalumab, an anti-B-cell-activating factor monoclonal antibody, for rheumatoid arthritis

Overview of attention for article published in Arthritis Research & Therapy, August 2014

Altmetric Badge

Mentioned by

So far, Altmetric has seen 1 X post from an account with 11,325 followers.

52-wk study to evaluate safety/efficacy of tabalumab, anti-B-cell activating factor monoclonal antibody in RA http://t.co/Wiv49AByLH #rheum

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.